Pomalidomide for Treatment of Relapsed and Refractory Multiple Myeloma
Pomalidomide is a third-generation immunomodulatory drug recommended for patients with multiple myeloma refractory to lenalidomide and bortezomib. The safety profile is optimized for application in patients with intensive and continuous anti-tumor treatment. Pomalidomide was approved by the Food and...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
Practical Medicine Publishing House
2015-10-01
|
| Edice: | Клиническая онкогематология |
| Témata: | |
| On-line přístup: | https://bloodjournal.ru/index.php/coh/article/view/564 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|